Minute Medical

MINUTEmedical stands for Molecular, Internal radioNUclide ThErapy of the highest quality and scientific excellence. Our expert medical team, Prof.

Outpatient clinic specialized in theranostics of prostate cancer (mCRPC) & neuroendocrine tumors: Lutetium-PSMA therapy, peptide radio receptor therapy (PRRT) using somatostatin analogues, therapy of bone metastases using radium-dichloride. Welcome to MINUTEmedical - private outpatient clinic in Vienna, Austria specialized in theranostics of metastatic castration-resistant prostate cancer (mCRPC)

and neuroendocrine tumours. We offer:
• PSMA therapy with Lutetium-177 or Actinium-225,
• Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues (e.g. [¹⁷⁷Lu]Lu-DOTA-TATE),
• Therapy of bone metastases using radium-223 dichloride (Xofigo®), and
• Molecular imaging ([⁶⁸Ga]Ga-PSMA-11, [⁶⁸Ga]Ga-DOTA-TATE PET-CT). Across Europe we are the only provider of these treatments in outpatient mode. Dr. Markus Hartenbach and Prof. Dr. Alexander Haug have extensive experience with these therapies: over 1000 [¹⁷⁷Lu]Lu-PSMA treatments in 8 years and over 12 years’ experience with [¹⁷⁷Lu]Lu-DOTA-TATE. Under the leadership of the prominent chemistry expert Prof. Dr. Wadzak, we produce the radiopharmaceuticals for you in our own radio-pharmacological laboratory, a so-called "hot lab". Our state-of-the-art clinic is equipped with the latest technology as demanded by the therapies we offer. We strive to provide the best care available. We thus designed the clinic so as to offer our patients the utmost in comfort, safety and discretion. All this is tailor-made to your needs and in the heart of one of the most beautiful cities in the world. Contact us for the first consultation.

24/05/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸New evidence from the -p trial (Nature Cancer) confirms that hormone therapy rapidly boosts PSMA expression in nearly 7 in 10 patients – creating a larger target for ¹⁷⁷Lu-PSMA therapy to exploit. The result: 13.1 vs 5.8 months progression-free survival. Personalised precision oncology, available at our clinic

🇩🇪Neue Erkenntnisse aus der ENZA-p-Studie (Nature Cancer) bestätigen, dass eine Hormontherapie die PSMA-Expression bei fast 7 von 10 |patienten rasch steigert und damit ein größeres Ziel für die ¹⁷⁷Lu-PSMA-Therapie schafft. Das Ergebnis: 13,1 vs. 5,8 Monate progressionsfreies Überleben. Personalisierte Präzisionsonkologie – in unserer Klinik verfügbar.

🇪🇸Nueva evidencia del ensayo ENZA-p (Nature Cancer) confirma que la terapia hormonal aumenta rápidamente la expresión de PSMA en casi 7 de cada 10 pacientes con , creando un blanco más amplio para la terapia con ¹⁷⁷Lu-PSMA. El resultado: 13,1 vs. 5,8 meses de supervivencia libre de progresión. Oncología de precisión personalizada, disponible en nuestra clínica.

🇭🇷Novi dokazi iz ispitivanja ENZA-p (Nature Cancer) potvrđuju da hormonska terapija brzo povećava ekspresiju PSMA u gotovo 7 od 10 bolesnika s rakom prostate, stvarajući veću metu za terapiju ¹⁷⁷Lu-PSMA. Rezultat: 13,1 vs. 5,8 mjeseci preživljenja bez progresije bolesti. Personalizirana precizijska onkologija, dostupna u našoj klinici.

12/05/2026

🇩🇪PSMA-Therapie in Österreich für privatversicherte und beihilfeberechtigte Patienten aus Deutschland
🇺🇸PSMA Therapy in Austria for Patients Insured in Germany

05/05/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸BULLSEYE: 2nd study after PSMAddition confirming ¹⁷⁷Lu-PSMA in hormone-sensitive prostate cancer & 1st before ADT
58 men with oligometastatic disease: 29 treated with ¹⁷⁷Lu-PSMA and 29 on active monitoring.
Results: median +20 months without hormone therapy in the PSMA arm vs watchful waiting, 7 patients with complete biochemical remission
🇩🇪BULLSEYE: 2. Studie nach PSMAddition, die ¹⁷⁷Lu-PSMA beim hormonsensitiven Prostatakarzinom bestätigt & 1. vor Beginn der ADT
58 Männer mit oligometastatischer Erkrankung: 29 mit ¹⁷⁷Lu-PSMA behandelt, 29 unter aktiver Überwachung
Ergebnisse: median +20 Monate ohne Hormontherapie im PSMA-Arm vs. Beobachtung, 7 Patienten mit kompletter biochemischer Remission
🇪🇸BULLSEYE: 2º estudio tras PSMAddition que confirma ¹⁷⁷Lu-PSMA en el cáncer de próstata hormonosensible y 1º antes de la ADT
58 hombres con enfermedad oligometastásica: 29 tratados con ¹⁷⁷Lu-PSMA y 29 en monitorización activa
Resultados: mediana de +20 meses sin hormonoterapia en el brazo PSMA vs observación, 7 pacientes con remisión bioquímica completa
🇭🇷BULLSEYE: 2. studija nakon PSMAddition koja potvrđuje ¹⁷⁷Lu-PSMA kod hormonski osjetljivog raka prostate i 1. prije ADT
58 muškaraca s oligometastatskom bolešću: 29 liječeno ¹⁷⁷Lu-PSMA, 29 na aktivnom praćenju
Rezultati: medijan +20 mjeseci bez hormonske terapije u PSMA skupini vs promatranje, 7 bolesnika s potpunom biokemijskom remisijom

14/04/2026

Evidence from the latest clinical trials RAPID, PRIMARY2 & PROMISE supports an imaging-first pathway to prostate cancer diagnosis: PSMA PET as a triage and risk stratification tool. Read in detail here 🇺🇸🇩🇪🇪🇸🇭🇷 → https://tinyurl.com/2kb654mf

05/04/2026

18/03/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸Read our new clinical case. Personalized theranostics in occult peritoneal carcinomatosis or how a carefully selected arsenal of isotopes, based on the latest clinical findings, paved the way to complete remission pf prostate cancer. https://tinyurl.com/3jvazcpk
🇩🇪Lesen Sie unseren neuen klinischen Fall. Individualisierte Theranostik bei okkulter Peritonealkarzinose oder wie ein sorgfältig ausgewähltes Isotopen-Arsenal auf Basis der neuesten klinischen Erkenntnisse den Weg zur kompletten Remission von Prostatakarzinom ebnete.
🇪🇸Lea nuestro nuevo caso clínico. Teranóstica personalizada en la carcinomatosis peritoneal oculta o cómo un arsenal de isótopos cuidadosamente seleccionado, basado en los hallazgos clínicos más recientes, abrió el camino hacia una remisión completa de cáncer de próstata.
🇭🇷Pročitajte naš novi klinički slučaj. Personalizovana teranostika kod okultne peritonealne karcinomatoze ili kako je pažljivo odabrani arsenal izotopa, rukovođen najnovijim kliničkim saznanjima, otvorio put ka kompletnoj remisiji karcinoma prostate.
Medisynt

12/02/2026

🇺🇸PSMA Radioligand therapy is moving earlier in the prostate cancer treatment sequence as a result of several clinical trials. https://tinyurl.com/4hu6rt5c
🇩🇪Die PSMA-Radioligandentherapie rückt aufgrund mehrerer klinischer Studien in eine frühere Phase der Prostatakrebsbehandlung vor.
🇪🇸La terapia con radioligandos PSMA se adelanta en la secuencia de tratamiento del cáncer de próstata como resultado de varios ensayos clínicos.
🇭🇷PSMA radioligandna terapija se pomera ka ranijim linijama lečenja raka prostate kao rezultat nedavnih kliničkih studija.

02/02/2026

Zadovoljstvo nam je da najavimo novu medicinsku saradnju, čiji je cilj da savremena terapija karcinoma prostate postane dostupnija pacijentima na Balkanu.
Kroz partnerstvo sa Ospita Diagnostics, prvim privatnim centrom u Beogradu koji nudi PSMA PET/CT dijagnostiku, pacijentima je omogućeno da:
• Obave PSMA PET/CT snimanje lokalno u Beogradu;
• Njihove nalaze razmatra zajednički međunarodni onkološki konzilijum;
• Prime specijalizovanu radioligandnu terapiju u našem centru u Beču.

We are pleased to announce a new medical cooperation designed to make advanced prostate cancer care more accessible for patients from the Balkan region.
Through our collaboration with Ospita Diagnostics, the only diagnostic center in Belgrade offering PET/CT, patients can now:
• Undergo PSMA PET/CT imaging locally in Belgrade
• Have their results reviewed by the joint interdisciplinary tumour board
• Receive specialized radioligand therapy at our center in Vienna

19/01/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸Adding ¹⁷⁷Lu-PSMA to standard treatment at the hormone-sensitive stage of prostate cancer proves beneficial. More side effects might be due to overtreatment. Increasing personalization of radioligand therapy might be the answer. At MINUTE Medical, this personalized, imaging-guided approach is already part of our routine practice, helping us determine the number of cycles, the radionuclides used, and the administered radiation dose.

🇩🇪Die Ergänzung der Standardtherapie durch ¹⁷⁷Lu-PSMA im hormonsensitiven Stadium des Prostatakarzinoms erweist sich als vorteilhaft. Mehr Nebenwirkungen könnten durch Überbehandlung verursacht werden. Eine verstärkte Personalisierung der Radioligandentherapie könnte die Lösung sein. Bei MINUTE Medical ist dieser personalisierte, bildgebungsbasierte Ansatz bereits Teil unserer routinemäßigen klinischen Praxis und hilft uns dabei, die Anzahl der Zyklen, die eingesetzten Radionuklide und die verabreichte Strahlendosis zu bestimmen.

🇪🇸La incorporación de ¹⁷⁷Lu-PSMA al tratamiento estándar en la fase hormonosensible del cáncer de próstata demuestra beneficios. Más efectos secundarios podrían deberse al sobretratamiento. Una mayor personalización de la terapia con radioligandos podría ser la respuesta. En MINUTE Medical, este enfoque personalizado y guiado por imagen ya forma parte de nuestra práctica habitual, ayudándonos a determinar el número de ciclos, los radionúclidos utilizados y la dosis de radiación administrada.

🇭🇷Dodavanje ¹⁷⁷Lu-PSMA standardnom lečenju u hormonski osetljivoj fazi karcinoma prostate pokazuje korist. Više nuspojava može biti posledica prekomernog lečenja. Sve veća personalizacija radioligandne terapije može biti rešenje. U MINUTE Medical-u je ovaj personalizovani, na PET/CT snimanju zasnovan pristup već deo naše rutinske kliničke prakse i pomaže nam da odredimo broj ciklusa, korišćene radionuklide i primenjenu dozu zračenja.

24/12/2025

Adresse

Innere Stadt
1090

Telefon

+4367762545515

Webseite

http://www.minute-medical.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Minute Medical erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.